Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $340.80 | 3 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Galderma Laboratories, L.P. | $124.91 | 1 | $0 (2019) |
| Incyte Corporation | $113.96 | 1 | $0 (2023) |
| LEO Pharma Inc. | $101.93 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $113.96 | 1 | Incyte Corporation ($113.96) |
| 2022 | $101.93 | 1 | LEO Pharma Inc. ($101.93) |
| 2019 | $124.91 | 1 | Galderma Laboratories, L.P. ($124.91) |
All Payment Transactions
3 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/29/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $113.96 | General |
| Category: Dermatology | ||||||
| 05/11/2022 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $101.93 | General |
| Category: DERMATOLOGY | ||||||
| 09/19/2019 | Galderma Laboratories, L.P. | ORACEA (Drug) | Food and Beverage | In-kind items and services | $124.91 | General |
| Category: ROSACEA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 7 | 194 | 286 | $20,313 | $8,600 |
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 36 | 40 | $5,200 | $2,338 | 45.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 37 | 43 | $3,655 | $1,845 | 50.5% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 55 | 71 | $3,910 | $1,577 | 40.3% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 15 | 19 | $2,460 | $1,175 | 47.8% |
| 17000 | Destruction of skin growth | Office | 2020 | 24 | 27 | $2,700 | $817.99 | 30.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 12 | 12 | $1,500 | $511.43 | 34.1% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 15 | 74 | $888.00 | $335.81 | 37.8% |
About Dr. Stanley Rekant, MD
Dr. Stanley Rekant, MD is a Dermatology healthcare provider based in Hammonton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2005. The National Provider Identifier (NPI) number assigned to this provider is 1154314052.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stanley Rekant, MD has received a total of $340.80 in payments from pharmaceutical and medical device companies, with $113.96 received in 2023. These payments were reported across 3 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($340.80).
As a Medicare-enrolled provider, Rekant has provided services to 194 Medicare beneficiaries, totaling 286 services with total Medicare billing of $8,600. Data is available for 1 year (2020–2020), covering 7 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Hammonton, NJ
- Active Since 08/25/2005
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1154314052
Products in Payments
- ORACEA (Drug) $124.91
- OPZELURA (Drug) $113.96
- ADBRY (Biological) $101.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.